IDEXX Laboratories (IDXX) Q4 2005 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2005 earnings summary
9 Nov, 2026Executive summary
Revenue rose 16% to $638.1M; organic growth was 10% before acquisitions and foreign-exchange effects, with all business areas contributing.
Continued investment in product development, customer relationships and talent supported long-term growth plans.
Financial highlights
Total revenue was $638.095M in 2005, up from $549.181M in 2004.
Operating income was $115.331M versus $108.035M; net income was $78.254M versus $78.332M.
Diluted EPS was $2.30 versus $2.19, up 5%; excluding discrete items in both years, diluted EPS grew 13%.
Operating cash flow increased to $116.552M from $95.379M.
Outlook and guidance
Long-term financial goals remain revenue growth above 10% and mid-teens EPS growth.
Growth opportunities include new products, geographic expansion, tuck-in acquisitions and greater connectivity across products and services.
Latest events from IDEXX Laboratories
- Revenue grew 25%, while margin pressure and Navigator charges weighed on earnings.IDXX
Q4 2007 - FY08 growth lifted revenue and earnings, while Q4 softened and regulatory risks mounted.IDXXQ4 2008
- Revenue rose 16%, organic growth accelerated, and adjusted EPS increased 23%.IDXXQ4 2006
- FY2010 growth lifted revenue to $1.103B as CAG and LPD gains offset economic headwinds.IDXXQ4 2010
- Direct-sales transition weighed on reported profit, but adjusted operating income grew 9.1%.IDXXQ4 2014
- CAG-led organic growth lifted FY13 revenue 6.7%, despite weaker LPD profitability.IDXXQ4 2013
- CAG growth lifted FY12 revenue and margins despite currency and livestock-testing headwinds.IDXXQ4 2012
- Recurring CAG diagnostics drove growth as FX headwinds and a software impairment tempered FY15 results.IDXXQ4 2015
- FY11 growth and stronger cash flow, offset by market and currency risks.IDXXQ4 2011